Literature DB >> 2539277

Epstein-Barr-virus-transformed lymphoblastoid cell lines derived from patients with X-linked agammaglobulinaemia and Wiskott-Aldrich syndrome: responses to B cell growth and differentiation factors.

Y L Lau1, J G Shields, R J Levinsky, R E Callard.   

Abstract

Epstein-Barr-virus-transformed B lymphoblastoid cell lines (EBV-transformed LCL) from three patients with X-linked agammaglobulinaemia (XLA), six patients with Wiskott-Aldrich Syndrome (WAS), and seven normal donors, were tested for growth and differentiation in response to human recombinant IL-4, a commercially available, low molecular weight B cell growth factor (BCGFlow), and B cell differentiation factor (BCDF) secreted by the T24 cell line, now known to be IL-6. Proliferation (3H-TdR uptake) by EBV-transformed LCL from both XLA and WAS patients in response to BCGFlow was similar to that obtained with the normal cell lines. In addition, three normal and three WAS, but none of the XLA EBV-transformed LCL, proliferated a little in response to IL-4. All the normal B cell lines secreted IgM, and six out of the seven secreted IgG in response to BCGFlow and BCDF. A similar pattern of response was obtained with the WAS EBV-transformed LCL (6/6 secreted IgM and 4/6 secreted IgG). Several of the normal and WAS EBV-transformed LCL also secreted IgM and IgG in response to IL-4. In contrast, the lines from the XLA patients were abnormal. One secreted large amounts of IgM and two secreted small amounts, but none of the XLA lines secreted IgG constitutively or in response to any of the factors (IL-4, BCDF). The lack of detectable IgG secretion by the XLA lines was probably due to an absence of precommitted IgG B cell precursors transformed by EBV rather than an intrinsic inability to respond to BCGF and BCDF. All of the lines, including those derived from XLA patients, were shown to secrete B cell growth and differentiation factors detected on indicator B cell lines. These results suggest that the abnormal X-linked genes responsible for XLA and WAS do not interfere with B cell responses to B cell growth and differentiation factors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539277      PMCID: PMC1542123     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Autocrine models of B-lymphocyte growth. I. Role of cell contact and soluble factors in T-independent B-cell responses.

Authors:  J Gordon; G Guy; L Walker
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

2.  Autocrine models of B-lymphocyte growth. II. Interleukin-1 supports the proliferation of transformed lymphoblasts but not the stimulation of resting B cells triggered through their receptors for antigen.

Authors:  J Gordon; G Guy; L Walker
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

3.  Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line.

Authors:  L Rimsky; H Wakasugi; P Ferrara; P Robin; J Capdevielle; T Tursz; D Fradelizi; J Bertoglio
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

4.  The importance of antibody quality in sandwich ELISA systems. Evaluation of selected commercial reagents.

Authors:  J G Shields; M W Turner
Journal:  J Immunol Methods       Date:  1986-02-27       Impact factor: 2.303

5.  Biosynthesis and secretion of immunoglobulins by peripheral-blood lymphocytes in severe hypogammaglobulinaemia.

Authors:  Y S Choi; W D Biggar; R A Good
Journal:  Lancet       Date:  1972-05-27       Impact factor: 79.321

6.  The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition.

Authors:  R M Blaese; W Strober; R S Brown; T A Waldmann
Journal:  Lancet       Date:  1968-05-18       Impact factor: 79.321

7.  Use of a human plaque-forming cell assay to study peripheral blood bursa-equivalent cell activation and excessive suppressor cell activity in humoral immunodeficiency.

Authors:  H G Herrod; R H Buckley
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

8.  B lymphocyte precursors in human bone marrow: an analysis of normal individuals and patients with antibody-deficiency states.

Authors:  E R Pearl; L B Vogler; A J Okos; W M Crist; A R Lawton; M D Cooper
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

9.  Wiskott-Aldrich syndrome: cellular impairments and their implication for carrier detection.

Authors:  J T Prchal; A J Carroll; J F Prchal; W M Crist; H W Skalka; W J Gealy; J Harley; A Malluh
Journal:  Blood       Date:  1980-12       Impact factor: 22.113

10.  Purification to homogeneity of a high molecular weight human B cell growth factor; demonstration of specific binding to activated B cells; and development of a monoclonal antibody to the factor.

Authors:  J L Ambrus; C H Jurgensen; E J Brown; A S Fauci
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Wiskott-Aldrich syndrome: a multidisciplinary disease.

Authors:  G R Standen
Journal:  J Clin Pathol       Date:  1991-12       Impact factor: 3.411

2.  Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia.

Authors:  N Ling; T Hansel; P Richardson; B Brown
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

3.  B-cell and T-regulatory cell dysfunction in six Chinese children with hypogammaglobulinaemia.

Authors:  B M Jones; Y L Lau; K L Wong
Journal:  Eur J Pediatr       Date:  1993-05       Impact factor: 3.183

4.  Defective B-cell and regulatory T-cell function in Wiskott-Aldrich syndrome.

Authors:  Y L Lau; B M Jones; L C Low; S N Wong; N K Leung
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.